(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.61%) $79.74
(1.48%) $2.34
(0.71%) $2 356.90
(0.71%) $28.57
(0.49%) $995.70
(0.09%) $0.928
(-0.05%) $10.86
(0.07%) $0.799
(0.17%) $92.70
0.22% $ 0.732
@ $1.235
Wydano: 12 vas. 2024 @ 22:35
Zwrot: -40.76%
Poprzedni sygnał: vas. 12 - 21:01
Poprzedni sygnał:
Zwrot: 2.06 %
Live Chart Being Loaded With Signals
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...
Stats | |
---|---|
Dzisiejszy wolumen | 909 888 |
Średni wolumen | 1.66M |
Kapitalizacja rynkowa | 129.37M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.140 ) 2024-08-01 |
Last Dividend | $12.19 ( 2012-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.280 |
ATR14 | $0.00400 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-28 | Tucker Sean | Buy | 0 | |
2024-03-28 | Tucker Sean | Sell | 3 902 | Common Stock |
2024-03-28 | Cummings James F. | Sell | 3 292 | Common Stock |
2024-03-18 | Tucker Sean | Buy | 90 000 | Common Stock |
2024-03-18 | Tucker Sean | Buy | 410 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
94.61 |
Last 95 transactions |
Buy: 10 890 181 | Sell: 279 805 |
Wolumen Korelacja
Vaxart Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
LYEL | 0.934 |
LYRA | 0.93 |
BNIXU | 0.929 |
TCRT | 0.92 |
WISA | 0.915 |
GROM | 0.914 |
AFMD | 0.914 |
ARQQ | 0.914 |
GRNA | 0.913 |
BNOX | 0.912 |
10 Najbardziej negatywne korelacje | |
---|---|
LRFC | -0.93 |
STAY | -0.928 |
GLLI | -0.907 |
IBEX | -0.905 |
OSMT | -0.904 |
XOMAO | -0.899 |
CHPM | -0.898 |
XOMAP | -0.898 |
BCOR | -0.895 |
MNKD | -0.893 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vaxart Inc Korelacja - Waluta/Towar
Vaxart Inc Finanse
Annual | 2023 |
Przychody: | $7.38M |
Zysk brutto: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2023 |
Przychody: | $7.38M |
Zysk brutto: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2022 |
Przychody: | $107 000 |
Zysk brutto: | $-3.16M (-2 953.27 %) |
EPS: | $-0.840 |
FY | 2021 |
Przychody: | $892 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
Vaxart Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.19 | 2012-11-09 |
Last Dividend | $12.19 | 2012-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.19 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $12.19 | 9.77% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -14.41 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.898 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.085 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.32 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.11 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.53 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0994 | -1.500 | 8.34 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -57.60 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.459 | 2.00 | -0.153 | -0.306 | [0 - 30] |
freeCashFlowPerShareTTM | -0.471 | 2.00 | -0.236 | -0.471 | [0 - 20] |
debtEquityRatioTTM | 0.158 | -1.500 | 9.37 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.196 | 1.000 | -0.0722 | -0.0722 | [0.2 - 0.8] |
operatingProfitMarginTTM | -14.56 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -7.72 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0623 | 0.800 | -2.92 | -2.33 | [0.5 - 2] |
Total Score | -1.818 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.358 | 1.000 | -0.238 | 0 | [1 - 100] |
returnOnEquityTTM | -1.085 | 2.50 | -8.46 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.471 | 2.00 | -0.157 | -0.471 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.459 | 2.00 | -0.153 | -0.306 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -12.31 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.59 |
Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej